Dietary Management in Slowing Down the Progression of CKDu

Abstract
Chronic kidney disease of unknown etiology (CKDu) is an emerging entity in the South Asian region. This predominately affects the farming community belonging to the lower socioeconomic status. CKDu being a progressive condition often leads to end-stage renal failure requiring renal replacement therapy (RRT). Due to the high cost and limited availability of RRT in many areas of geographical locations in India and worldwide, there is an unmet need to slow down the progression of CKDu. The intestinal microbiota is different in patients with CKD, with low levels of beneficial bacteria such as _Lactobacillus_ and _Bifidobacteria_. Prebiotics and probiotics modify the intestinal microbiota and thereby slow down the progression. Soda bicarbonate therapy is cheap and cost-effective in slowing down the progression of CKDu in a subset of patients. There is also evidence of the beneficial effect of N-acetyl cysteine in early stages of CKD and it should benefit CKDu also. Dietary interventions to prevent dehydration, by providing uncontaminated drinking water, sufficient protein containing diet with adequate calories, and tailored salt intake to prevent hypotension, are necessary compared to other causes of CKD. The objective is to prevent malnutrition, and uremic symptoms. Early diagnosis and prompt intervention may delay the progression of CKDu in the early stages.

Keywords: CKDu, malnutrition, nutritional therapy

Introduction
The first report by the CKD registry documents prevalence rate of 16% for chronic kidney disease of unknown etiology (CKDu) in India with 21.3% in the southern part of India.[1] Uddanam in Sriakulam district consisting of the mandals of Kavitti, Sompeta, Kanchili, Ithapuram, Palas, and Vajrapukotturu and Prakasham district of Andhra Pradesh, Goa, and Odisha [Figure 1] have higher prevalence of CKDu especially among the younger farming population.[2] Several causative associations such as farming occupation, exposure to residual pesticides, high content of cadmium and silica in the drinking water, and genetic predisposition have been thought to be involved in the pathogenesis of CKDu.[1]

Intestinal Flora among Healthy Individuals and in Patients with CKD
There is a paucity of data on intestinal microflora in South Asian population in health and disease states. The human gut harbors more than 100 trillion bacterial cells in healthy individuals, which is predominately rich in bacteria such as _Lactobacillus_ and _Bifidobacteria_. Whereas in uremic patients, higher levels of pathogens such as _Clostridia_, _Enterobacteria_ sp., and _Pseudomonas_ sp. are found, with low level of _Lactobacillus_ and _Bifidobacteria_.[3] Patients with end-stage renal disease (ESRD) are also at a higher risk of _Clostridium difficile_–associated diarrhea.

Dysbiosis refers to an imbalance in the composition of the gut microbiome. Increased secretion and hydrolysis of urea leads to excessive formation of ammonia, thereby affecting the growth of gut commensal bacteria. Gut bacteria produces endotoxins which lead to an inflammatory response in the host organism. Moreover, protein fermentation by the gut microbes produces toxic metabolites, such as p-cresol and indoxyl sulfate.[4] P-cresol is largely conjugated to p-cresylsulfate (PCS) in the intestinal wall and subsequently to p-cresyl glucuronide in the liver.[5] In CKDu like other CKD, the barrier function of the gut is disrupted causing translocation of the endotoxins and bacterial metabolites into the systemic circulation which contributes to the uremic

For reprints contact: reprints@medknow.com

How to cite this article: Anupama PH, Prasad N, Nzana VB, Tiwari JP, Mathew M, Abraham G. Dietary management in slowing down the progression of CKD. Indian J Nephrol 2020;30:256-60.
Toxicity, inflammation, associated cardiovascular disease, and progression of CKD.⁵ The concentration of indoxyl sulfate and PCS in the serum is negatively correlated with kidney function.⁶ The colonic transit time is approximately 14 h among South Asians. However, in patients with any CKD, the transit time is further prolonged, contributing to increased absorption of uremic substances. Furthermore, vitamin K deficiency or insufficiency is common among patients with any CKD due to decreased synthesis by Bacteroides fragilis, Bifidobacteria, Clostridium sp, and Streptococcus faecalis. Hence, bacterial metabolism-based interventions may be of therapeutic importance in any CKD including CKDu [Figure 2].

Sources of prebiotics include breast milk, soybeans, raw oats, unrefined wheat, unrefined barley, non-digestible carbohydrates, and in particular nondigestible oligosaccharides.⁹

The most commonly used probiotic strains are Bifidobacterium, Lactobacillus rhamnosus, Lactobacillus reuteri and certain strains of Lactobacillus casei, Saccharomycesboulardii, and Bacillus coagulans. Foods containing probiotics include fermented dairy products such as yogurt, kefir, and cheese.

Therapeutic Modulation of Gut Microbiome

Prebiotics promote growth of Bifidobacteria and Lactobacillus species, whereas they reduce certain bacteria such as Bacteroidesp, Clostridia sp, and Enterobacteria.⁵ Oligofructose-enriched inulin promotes growth of Bifidobacteria sp, mediates weight loss, reduces inflammation, and improves metabolic function [Figure 2].⁵ Meijers et al. reported a decrease in serum concentration of p-cresol after oral intake of oligofructose-enriched inulin in hemodialysis patients.⁴ High dietary fiber consumption lowers the risk of inflammation and reduces mortality in patients with any CKD.⁴ Streptococcus thermophilus (KB19), Lactobacillus acidophilus (KB27), and Bifidobacterium longum (KB31) produce bacteriocins, namely, lactacin and bisin which inhibit the growth of pathogens, thereby reducing generation of uremic toxins. Streptococcus thermophiles metabolizes urea, uric acid, and creatinine. Bifidobacterium longum reduces the level of protein-bound uremic toxins such as phenols and cresols.

Role of Oral Bicarbonate Supplementation

Metabolic acidosis is a common complication in advanced stages of any CKD. This is often associated with increased protein catabolism due to the upregulation of the ubiquitin-proteasome system, excessive oxidation of branched chain amino acids, and reduced synthesis of visceral proteins including albumin.¹⁵ In a randomized, prospective study in London by Brito-Ashurst et al., 134 patients with creatinine clearance of 30–15 mL/min/1.73 m² was given either oral sodium bicarbonate tablets 600 mg thrice daily dose adjusted to achieve and maintain HCO₃⁻ level ≥23 mmol/L or routine standard care. Serum bicarbonate was measured every 2 months. The rate of decline in creatinine clearance in stage 4 CKD was found to be lower among individual on bicarbonate therapy (1.88 mL/min/1.73 m²) when compared with the control group (5.93 mL/min/1.73 m²).¹⁵ Oral bicarbonate supplementation is an affordable and accessible means of maintaining serum bicarbonate >22 mmol/L.

N-Acetyl Cysteine

N-acetyl cysteine (NAC) use reduced the risk of progression of CKD of any etiology to ESRD significantly (18%).¹⁶ However, the mechanism by which NAC reduces the progression of CKD to ESRD is unclear. It may be attributed to the antioxidant and vasodilatory nature of NAC.¹⁶ Prolonged duration of administration and higher dosage of NAC increase its renal protective effect.¹⁶,¹⁷ Due to its low cost, wide availability, and ease of administration, it is widely accepted.

Conservative Management of CKDu

Consumption of uncontaminated water, avoidance of nephrotoxic drugs, chewing practices with concoction, and limited exposure to pesticides and agrochemicals² are some of the measures in delaying the progression of CKDu. Supportive care should include anemia correction, skilled dietician advice, and regular follow-up. Prebiotics and probiotics may be effective in partially reducing the colonic transit time. Hence, slowing the progression of CKDu.
Soda bicarbonate therapy and NAC will provide value to the management of CKDu in low-resource setting.\(^{[15]}\)

**Dietary advice**

As CKDu is a nonproteuric disease, dietary advice of protein intake with 0.6 g/kg/day or a very low protein diet of 0.3 g/kg/day with ketoanalogues, 30–35 kCal/kg/day supplemented with micro nutrients may slow down the progression by reduction in serum phosphate and FGF-23 levels.\(^{[18]}\) As in CKD low protein diet would reduce urea production, advanced glycation end products, and waste products of protein metabolism such as indoxyl sulfate, PCS, and trimethylamine N-oxide.\(^{[19]}\)

**Discussion**

A review of literature showed several studies analyzing the association of prebiotics and probiotics with CKD of other known etiology but none with CKDu. Use of prebiotics and probiotics has been proven to slow down the progression of CKD, and the same may be applied in patients with CKDu.

Ranganathan conducted a 6-month prospective clinical trial assessing the biochemical and clinical effects of an oral probiotics [90 billion colony-forming units (CFUs)] in 16 stage 3 and stage 4 patients with CKD, out of which 13 completed the study. The major outcome included a reduction in blood urea nitrogen (BUN), serum creatinine, and uric acid.\(^{[20]}\)

Similarly, Paola Vanessa *et al.* conducted a study on the effect of probiotics on BUN levels in 30 patients with stage 3 and stage 4 CKD. The study was aimed to determine the effectiveness of two dosing of *Lactobacillus casei* Shirota, 8 × 10⁹ CFUs and 16 × 10⁹ CFUs in achieving a decrease in the serum urea concentration. Patients with CKD show an increase in aerobic bacteria which produce uremic toxins in the bowel, with decreased anaerobic bacteria such as...
Lactobacillus and Bifidobacteria. Patients were followed up for 8 weeks on the probiotic supplementation. A decrease of more than 10% was found in the concentration of blood urea and serum creatinine, noted in the population treated with higher dose of probiotics.[21]

Rathi et al. conducted a study administering enteric coated gelatin capsules containing lyophilized Streptococcus thermophilus, Lactobacillus acidophilus, and Bifidobacterium longum in a dose of 15 million CFUs along with lactitol monohydrate as prebiotic to 30 predialysis CKD patients. The results showed significant improvement in various parameters of CKD.[22]

Jia et al. conducted a meta-analysis that showed probiotics supplementations may reduce the levels of PCS and elevate the levels of IL-6 which are found to be beneficial.[23,24]

According to the WHO and the FAO (2002), “Probiotics may theoretically be responsible for 4 types of side effects such as systemic infections, deleterious metabolic activities, excessive immune stimulation in susceptible individuals and gene transfer.”

Most patients with CKDu belong to lower socioeconomic status and they have chronic tubulointerstitial disease. Tubulointerstitial disease which is progressive; dehydration and salt loss is highly probable, and protein energy malnutrition with micronutrient deficiencies are not addressed in this CKDu lower socioeconomic strata population. Dietary advice targeted to this population is an important critical component of the treatment. Patients with CKDu are at high risk of dehydration and dehydration-related acute on chronic kidney injury due to their tubulointerstitial diseases. Special diet catering to the communities where CKDu prevalence is high, providing appropriate calories and proteins as per stage of CKD should be emphasized.[25,26]

Conclusion

Prebiotics and probiotics alter the microbiome of the gastrointestinal system, thereby reducing the production of uremic toxins, aid in slowing down the progression of CKD. Soda bicarbonate therapy ameliorates any CKD progression. Nutritional monitoring and targeted nutritional therapy, as per the critical needs of the vulnerable CKDu patients, is of utmost importance in preventing malnutrition, dehydration, and uremic symptoms. There is an unmet need to look at the etiology of CKDu in the South Asian region and tailor the nutritional therapy in the low-resource setting.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

19. Locatelli F, Bárány P, Covic A, De Francesco A, Del Vecchio L,


